Peptide / GH Axis

Tesamorelin

FDA-approved GHRH analog (brand: Egrifta) for HIV-associated lipodystrophy. Reduces visceral fat 10–15% in trials. Most clinically validated GHRH.

Build protocol outline Open dose calculator TNHL ebooks

Educational reference only. This page does not diagnose, prescribe, or replace care from a licensed professional. Laws, availability, and clinical appropriateness vary by location.

Reference dose1–2 mg SubQ once daily

Half-life0.6 hours

Risk flaglow

Regulatory noteFDA-approved context noted

Side effects and watch-outs

Injection site reactions
Arthralgia
Peripheral oedema
Paraesthesia
Nausea
Glucose intolerance